Overview of therapeutic drug monitoring
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Ju-Seop | - |
dc.contributor.author | Lee, Min-Ho | - |
dc.date.accessioned | 2022-12-20T22:55:38Z | - |
dc.date.available | 2022-12-20T22:55:38Z | - |
dc.date.created | 2022-09-16 | - |
dc.date.issued | 2009-03 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/177094 | - |
dc.description.abstract | Therapeutic drug monitoring (TDM) is the clinical practice of measuring specific drugs at designated intervals to maintain a constant concentration in a patient's bloodstream, thereby optimizing individual dosage regimens. It is unnecessary to employ TDM for the majority of medications, and it is used mainly for monitoring drugs with narrow therapeutic ranges, drugs with marked pharmacokinetic variability, medications for which target concentrations are difficult to monitor, and drugs known to cause therapeutic and adverse effects. The process of TDM is predicated on the assumption that there is a definable relationship between dose and plasma or blood drug concentration, and between concentration and therapeutic effects. TDM begins when the drug is first prescribed, and involves determining an initial dosage regimen appropriate for the clinical condition and such patient characteristics as age, weight, organ function, and concomitant drug therapy. When interpreting concentration measurements, factors that need to be considered include the sampling time in relation to drug dose, dosage history, patient response, and the desired medicinal targets. The goal of TDM is to use appropriate concentrations of difficult-to-manage medications to optimize clinical outcomes in patients in various clinical situations. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KJIM | - |
dc.title | Overview of therapeutic drug monitoring | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kang, Ju-Seop | - |
dc.identifier.doi | 10.3904/kjim.2009.24.1.1 | - |
dc.identifier.scopusid | 2-s2.0-64249134394 | - |
dc.identifier.bibliographicCitation | Korean Journal of Internal Medicine, v.24, no.1, pp.1 - 10 | - |
dc.relation.isPartOf | Korean Journal of Internal Medicine | - |
dc.citation.title | Korean Journal of Internal Medicine | - |
dc.citation.volume | 24 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 10 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART001322551 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | aminoglycoside antibiotic agent | - |
dc.subject.keywordPlus | amiodarone | - |
dc.subject.keywordPlus | antibiotic agent | - |
dc.subject.keywordPlus | digoxin | - |
dc.subject.keywordPlus | erythromycin | - |
dc.subject.keywordPlus | phenytoin | - |
dc.subject.keywordPlus | procainamide | - |
dc.subject.keywordPlus | theophylline | - |
dc.subject.keywordPlus | vancomycin | - |
dc.subject.keywordPlus | warfarin | - |
dc.subject.keywordPlus | age | - |
dc.subject.keywordPlus | analytic method | - |
dc.subject.keywordPlus | body weight | - |
dc.subject.keywordPlus | clinical practice | - |
dc.subject.keywordPlus | drug absorption | - |
dc.subject.keywordPlus | drug blood level | - |
dc.subject.keywordPlus | drug distribution | - |
dc.subject.keywordPlus | drug elimination | - |
dc.subject.keywordPlus | drug half life | - |
dc.subject.keywordPlus | drug monitoring | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | nephrotoxicity | - |
dc.subject.keywordPlus | outcome assessment | - |
dc.subject.keywordPlus | prescription | - |
dc.subject.keywordPlus | review | - |
dc.subject.keywordPlus | sampling | - |
dc.subject.keywordPlus | sensitivity and specificity | - |
dc.subject.keywordPlus | therapy effect | - |
dc.subject.keywordPlus | algorithm | - |
dc.subject.keywordPlus | dose response | - |
dc.subject.keywordPlus | forecasting | - |
dc.subject.keywordPlus | methodology | - |
dc.subject.keywordPlus | patient compliance | - |
dc.subject.keywordPlus | pharmacokinetics | - |
dc.subject.keywordPlus | Algorithms | - |
dc.subject.keywordPlus | Dose-Response Relationship, Drug | - |
dc.subject.keywordPlus | Drug Monitoring | - |
dc.subject.keywordPlus | Forecasting | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Patient Compliance | - |
dc.subject.keywordPlus | Pharmacokinetics | - |
dc.subject.keywordAuthor | Drug monitoring | - |
dc.subject.keywordAuthor | Pharmacokinetics | - |
dc.subject.keywordAuthor | Therapeutic | - |
dc.identifier.url | https://www.kjim.org/journal/view.php?doi=10.3904/kjim.2009.24.1.1 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.